BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 17079451)

  • 1. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
    Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
    Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
    Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
    J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
    Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
    Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
    Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
    FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of retinal neovascularization by soluble EphA2 receptor.
    Chen J; Hicks D; Brantley-Sieders D; Cheng N; McCollum GW; Qi-Werdich X; Penn J
    Exp Eye Res; 2006 Apr; 82(4):664-73. PubMed ID: 16359662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
    Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A
    Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions.
    Sharfe N; Nikolic M; Cimpeon L; Van De Kratts A; Freywald A; Roifman CM
    Mol Immunol; 2008 Mar; 45(5):1208-20. PubMed ID: 17980912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions.
    Hainaud P; Contrerès JO; Villemain A; Liu LX; Plouët J; Tobelem G; Dupuy E
    Cancer Res; 2006 Sep; 66(17):8501-10. PubMed ID: 16951162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival.
    Chen Z; Varney ML; Backora MW; Cowan K; Solheim JC; Talmadge JE; Singh RK
    Cancer Res; 2005 Oct; 65(19):9004-11. PubMed ID: 16204074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
    Reynolds AR; Reynolds LE; Nagel TE; Lively JC; Robinson SD; Hicklin DJ; Bodary SC; Hodivala-Dilke KM
    Cancer Res; 2004 Dec; 64(23):8643-50. PubMed ID: 15574772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y; Opeskin K; Goad J; Williams ED
    Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
    Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
    Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization.
    Wang W; Wu F; Fang F; Tao Y; Yang L
    Cancer Sci; 2008 Oct; 99(10):2012-8. PubMed ID: 19016761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proangiogenic factor ephrin-A1 is up-regulated in radioresistant murine tumor by irradiation.
    Nojiri K; Iwakawa M; Ichikawa Y; Imadome K; Sakai M; Nakawatari M; Ishikawa K; Ishikawa A; Togo S; Tsujii H; Shimada H; Imai T
    Exp Biol Med (Maywood); 2009 Jan; 234(1):112-22. PubMed ID: 18997097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model.
    Shibata MA; Morimoto J; Shibata E; Otsuki Y
    Cancer Gene Ther; 2008 Dec; 15(12):776-86. PubMed ID: 18654613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
    Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.